SCHEMBL370237

SCHEMBL370237

C=CCOc1nn(Cc2ccc(OC)cc2)cc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.47
CHRM1 P11229 2/20 0.43
AADAT Q8N5Z0 1/20 0.41
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 2/20 0.41
GAA P10253 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
CACNA1G O43497 1/20 0.40
CACNA1H O95180 1/20 0.40
CACNA1I Q9P0X4 1/20 0.40
FLT3 P36888 1/20 0.40
TP53 P04637 2/20 0.39
USP2 O75604 1/20 0.39
ASPH Q12797 2/20 0.38
KDM8 Q8N371 2/20 0.38
TSHR P16473 2/20 0.38
CYP19A1 P11511 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL370874 0.91 FLT3 (0.42) KMT2ACHRM1AADATKDM4EMEN1
SCHEMBL368884 0.90 BLM (0.42) KMT2AAADATKDM4EMEN1GAA
SCHEMBL370510 0.86 FLT3 (0.39) KMT2AAADATKDM4EMEN1GAA
SCHEMBL25205458 0.85 KMT2A (0.55) KMT2ACHRM1AADATMEN1ALDH1A1
SCHEMBL370661 0.85 KDM4E (0.43) KMT2AKDM4EMEN1GAAALDH1A1
SCHEMBL6837102 0.81 KMT2A (0.51) KMT2ACHRM1AADATMEN1NPC1
SCHEMBL370873 0.79 AADAT (0.39) KMT2AAADATKDM4EMEN1GAA
SCHEMBL370507 0.78 KMT2A (0.53) KMT2ACHRM1AADATMEN1NPC1
SCHEMBL370508 0.78 KMT2A (0.53) KMT2ACHRM1MEN1NPC1RAB9A
SCHEMBL1047554 0.78 KMT2A (0.55) KMT2ACHRM1AADATKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 KMT2A 1638/4885CHRM1 250/4885AADAT 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.